Anti-Diabetes

Diabetes is a group of metabolic diseases characterized by high blood sugar. Hyperglycemia is due to insulin secretion defects or their biological effects of damage, or both caused. Hyperglycemia in long-term diabetes, leading to various tissues, especially the eyes, kidneys, heart, blood vessels, nerve chronic damage, dysfunction. The etiology of diabetes is roughly one is Genetic factors. Type 1 or type 2 diabetes had significant genetic heterogeneity. There is a family history of diabetes mellitus, 1/4 ~ 1/2 patients with family history of diabetes. Clinically at least 60 kinds of genetic syndromes may be associated with diabetes. Second, Environmental factors, eating too much, reduce physical activity caused by obesity is the most important environmental factors of type 2 diabetes, so that type 2 diabetes genetic susceptibility to individuals prone to disease. There is no cure for diabetes, but through a variety of treatment can control diabetes. Mainly includes five aspects: diabetes education, self-monitoring of blood sugar, diet therapy, exercise therapy and drug treatment. Antidiabetic drugs are needed in the patient after eating and exercise therapy and diabetes health education, blood sugar control can not be achieved when the target treatment. Most antidiabetic drugs have a greater side effect, so the patient must follow the doctor's instructions. With the succession of new antidiabetic drug patents,the patient is not only actually reducing the cost of treatment, but also increased the number of treatment options, Take greater hopes to patients with disease control.


Intermediate of Duloxetine Hydrochloride 116539-55-0
Intermediate of Duloxetine Hydrochloride 116539-55-0
Sitagliptin Intermediate CAS 486460-00-8
Sitagliptin Intermediate CAS 486460-00-8
Sitagliptin Intermediate CAS 762240-92-6
Sitagliptin Intermediate CAS 762240-92-6
Sitagliptin CAS 486460-32-6
Sitagliptin CAS 486460-32-6
Canagliflozin Intermediate 3 CAS 898566-17-1
Canagliflozin Intermediate 3 CAS 898566-17-1
Canagliflozin Intermediate 4 CAS Number 1030825-20-7
Canagliflozin Intermediate 4 CAS Number 1030825-20-7
Empagliflozin Intermediate 6 CAS NUMBER 915095-94-2
Empagliflozin Intermediate 6 CAS NUMBER 915095-94-2
2-[(5-bromo-2-fluorophenyl)Methyl]-Benzo[b]thiophene Used for Ipragliflozin CAS  1034305-17-3
2-[(5-bromo-2-fluorophenyl)Methyl]-Benzo[b]thiophene Used for Ipragliflozin CAS 1034305-17-3
Senior Intermediate of Lubiprostone 136790-77-7
Senior Intermediate of Lubiprostone 136790-77-7
4-Iodo-1-chloro-2-(4-ethoxybenzyl)benzene For Ertugliflozin 1103738-29-9
4-Iodo-1-chloro-2-(4-ethoxybenzyl)benzene For Ertugliflozin 1103738-29-9
ERTUGLIFLOZIN Called PF-04971729;PF04971729 CAS 1210344-57-2
ERTUGLIFLOZIN Called PF-04971729;PF04971729 CAS 1210344-57-2
(5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone For Ertugliflozin 1103738-26-6
(5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone For Ertugliflozin 1103738-26-6
Diabetes Mellitus Treatment Durg Sitagliptin Cas Number 486460-32-6
Diabetes Mellitus Treatment Durg Sitagliptin Cas Number 486460-32-6
(S)-(-)-N,N-Dimethyl-3-Hydroxy-3-(2-Thienyl)Propanamine CAS 132335-44-5
(S)-(-)-N,N-Dimethyl-3-Hydroxy-3-(2-Thienyl)Propanamine CAS 132335-44-5

© 2019 CHINA WAY. All Rights Reserved.  Taizhou Volsen Chemical Co., Ltd.,  Inc.   All rights reserved. site map.  sitemap.html